Meridian Bioscience/ US5895841014 /
| 2023-01-30 10:00:00 PM | Chg. - | Volume | Bid1:50:00 AM | Ask1:50:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 33.9700USD | - | 6.42 mill. Turnover: 176.77 mill. |
33.7000Bid Size: - | 33.9900Ask Size: - | 1.5 bill.USD | - | 35.02 |
Assets
|
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 29.9950 | 30.5670 | 31.1200 | 43.2140 | 44.8580 | ||||||
| Intangible Assets | 23.1130 | 60.2430 | 83.1970 | 84.1510 | 74.1310 | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | 112.3240 | 180.7170 | 243.0710 | 256.9150 | 252.5000 | ||||||
| Inventories | 41.9930 | 39.6170 | 61.2640 | 76.8420 | 67.8140 | ||||||
| Accounts Receivable | 32.3360 | 35.6080 | 38.5120 | 53.5680 | 47.2350 | ||||||
| Cash and Cash Equivalents | 59.7630 | 62.3970 | 53.5140 | 49.7710 | 81.4530 | ||||||
| Current Assets | 139.0530 | 144.7610 | 162.1900 | 192.8070 | 210.5970 | ||||||
| Total Assets | 251.3770 | 325.4780 | 405.2610 | 449.7220 | 463.0970 | ||||||
Liabilities
|
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 6.2600 | 7.2380 | 11.9690 | 11.7010 | 17.7590 | ||||||
| Long-term debt | 44.9300 | 75.8240 | 68.8240 | 60 | 25 | ||||||
| Liabilities to Banks | - | - | - | - | - | ||||||
| Provisions | 3.8000 | 2.5000 | 3.8000 | - | - | ||||||
| Liabilities | 75.9590 | 134.5110 | 157.6320 | 121.4200 | 95.0360 | ||||||
| Share Capital | - | - | - | - | - | ||||||
| Total Equity | 175.4180 | 190.9670 | 247.6290 | 328.3020 | 368.0610 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 251.3770 | 325.4780 | 405.2610 | 449.7220 | 463.0970 | ||||||
Income Statement
|
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 213.5710 | 201.0140 | 253.6670 | 317.8960 | 333.0180 | ||||||
| Depreciation (total) | 7.9240 | 9.9640 | 13.5670 | 15.2860 | 16.5110 | ||||||
| Operating Result | 31.5840 | 32.6990 | 61.3240 | 93.0340 | 54.3910 | ||||||
| Interest Income | -1.1020 | -1.2640 | -2.4900 | -1.8780 | -1.1720 | ||||||
| Income Before Taxes | 30.3800 | 31.5570 | 59.2930 | 90.4510 | 54.3170 | ||||||
| Income Taxes | 6.5310 | 7.1750 | 13.1070 | 19.0440 | 11.8580 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | 23.8490 | 24.3820 | 46.1860 | 71.4070 | 42.4590 | ||||||
Per Share
Cash Flow
|
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 34.7830 | 35.8310 | 47.9760 | 66.8650 | 82.3610 | ||||||
| Cash Flow from Investing Activities | -4.2010 | -48.4520 | -54.5980 | -40.3970 | -11.1150 | ||||||
| Cash Flow from Financing | -27.5930 | 15.2600 | -3.5570 | -31.0690 | -34.3030 | ||||||
| Decrease / Increase in Cash | 2.6910 | 1.6340 | -8.8830 | -3.7430 | 31.6820 | ||||||
| Employees | 400 | 485 | 560 | - | - | ||||||
